ASCO and CollabRx Partner to Develop Online Apps for Cancer Treatment Targeted to Molecular Subtypes
April 27, 2011
ASCO and CollabRx Partner to Develop Online Apps for Cancer Treatment Targeted to Molecular Subtypes
ASCO and CollabRX announced a partnership that will focus, at first, on CollabRx’s Targeted Therapy Finder -- Melanoma, a web application that allows patients to search for treatments based on the molecular characteristics of their cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CollabRx Expands Treatment Guidance to Lung Cancer, Partners with CAP for Patient Outreach
February 29, 2012 / Pharmacogenomics Reporter - Jackson Lab Collecting Cancer Mutation Data in Mouse Avatars to Support PGx Studies
September 5, 2012 / Pharmacogenomics Reporter - U Michigan Partnering with IGC to Create Sequencing-Based PGx Non-Profit
September 5, 2012 / Pharmacogenomics Reporter - Roche, BMS Hope to Improve Outcomes in BRAF-Mutated Melanoma Patients with Dual Treatment Regimen
June 8, 2011 / Pharmacogenomics Reporter - Response Genetics Licenses BRAF Mutation Technology to GlaxoSmithKline
May 11, 2010 / GenomeWeb Daily News